BioMerieux SA

BIM: XPAR (FRA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
?>LOCK|Bm^JLOCK|JQd%@v

BioMérieux: Maintaining a Narrow Moat Rating After Taking a Fresh Look; Shares Are Fairly Valued

Business Strategy and Outlook

BioMérieux is a specialist in the fragmented in vitro diagnostics market, with expertise in microbiology testing and syndromic molecular testing. The company is also active in the immunoassays market.

Sponsor Center